Trials / Recruiting
RecruitingNCT04539301
Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,100 (estimated)
- Sponsor
- Nantes University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Despite their usefulness in perioperative and acute care settings, factor-Xa inhibitors-specific assays are scarcely available, contrary to heparin anti-Xa assay. The investigators aimed at assessing whether the widely used heparin anti-Xa assay can quantify the apixaban, rivaroxaban, fondaparinux and danaparoid levels.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Estimated anticoagulant level (conversion factor x anti-Xa activity) | Estimated anticoagulant level (conversion factor x anti-Xa activity) |
Timeline
- Start date
- 2021-04-01
- Primary completion
- 2024-05-01
- Completion
- 2024-05-01
- First posted
- 2020-09-04
- Last updated
- 2024-05-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04539301. Inclusion in this directory is not an endorsement.